Emphasizing collaborative innovation, the consortium invites participation from small and medium-sized enterprises (SMEs), large local enterprises (LLEs), and other multinational corporations (MNCs) as service and technology providers. This collaborative approach is designed to facilitate the translation of technologies developed within the consortium, enabling companies to swiftly respond to pandemic-induced demands for biopharmaceutical products, thus ensuring broader patient access and other benefits.

In 2022, consortium partners executed a Memorandum of Understanding, engaging in exploratory discussions to pinpoint manufacturing challenges and outline research objectives. These discussions, facilitated by A*STAR and EDB, have led to initiatives focusing on leveraging data analytics for process enhancement and pursuing agile, sustainable manufacturing solutions.

Professor Lim Keng Hui from A*STAR emphasized the consortium's role in bolstering Singapore's biomanufacturing field, aligning with the nation's Manufacturing 2030 vision for increased manufacturing value. Cindy Koh of EDB highlighted the consortium's potential to fortify Singapore's global standing as a biopharma manufacturing hub, enhancing local ecosystem and workforce capabilities.

Quotes from BioPIPS members underscore the collaborative ethos and strategic vision underpinning the consortium. BioNTech, GSK, and Sanofi leaders expressed their commitment to advancing manufacturing innovations and environmental sustainability. Academia representatives from NTU, NUS, and SIT stressed the importance of interdisciplinary research, operational efficiency, and applied learning in achieving the consortium's goals, marking a new chapter in Singapore's journey towards becoming a leading biologics manufacturing and innovation hub.